Organ Damage and Quality of Life in Antiphospholipid Syndrome
- PMID: 26769306
- DOI: 10.1007/s11926-015-0556-6
Organ Damage and Quality of Life in Antiphospholipid Syndrome
Abstract
Antiphospholipid syndrome (APS) affects young patients in the most productive years of their life, and the consequences of organic or tissue damage involve a decrease in health-related quality of life (HRQoL). While acute disease manifestations of APS are well known, information on the long-term prognosis and damage in affected patients is still very limited. Systemic lupus erythematosus (SLE) patients would be expected to experience long-term complications and even die as a consequence of APS. Organ damage in APS has been evaluated using different methods and definitions, including the SLICC/ACR Damage Index (SDI), which tend to underestimate aPL-related damage. A new damage index in APS has been proposed (DIAPS), and it seems to be more accurate than SDI. Given the implications for morbidity and mortality, it is imperative to assess accurately aPL-related damage and HRQoL in patients with APS.
Keywords: Antiphospholipid syndrome (APS); Damage index in APS (DIAPS); Health-related quality of life (HRQoL); Organ damage; Quality of life; SLICC/ACR Damage Index (SDI); Systemic autoimmune diseases (SAD).
Similar articles
-
Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus.Lupus. 2020 Mar;29(3):256-262. doi: 10.1177/0961203320901598. Epub 2020 Jan 27. Lupus. 2020. PMID: 31986962
-
Health-Related Quality of Life in Antiphospholipid Syndrome: Current Knowledge and Future Perspectives.Curr Rheumatol Rep. 2020 May 13;22(6):20. doi: 10.1007/s11926-020-00900-z. Curr Rheumatol Rep. 2020. PMID: 32405870 Review.
-
High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus.Arch Intern Med. 2004 Jan 12;164(1):77-82. doi: 10.1001/archinte.164.1.77. Arch Intern Med. 2004. PMID: 14718326
-
Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS).Lupus. 2015 Aug;24(9):927-34. doi: 10.1177/0961203315576858. Epub 2015 Mar 11. Lupus. 2015. PMID: 25767071
-
The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes.Lupus. 2014 May;23(6):507-17. doi: 10.1177/0961203313501402. Lupus. 2014. PMID: 24763535 Review.
Cited by
-
Navigating antiphospholipid syndrome: from personalized therapies to cutting-edge research.Rheumatol Adv Pract. 2025 Jan 8;9(1):rkaf005. doi: 10.1093/rap/rkaf005. eCollection 2025. Rheumatol Adv Pract. 2025. PMID: 39846052 Free PMC article. Review.
-
Pediatric antiphospholipid syndrome: clinical features and therapeutic interventions in a single center retrospective case series.Pediatr Rheumatol Online J. 2022 Feb 23;20(1):17. doi: 10.1186/s12969-022-00677-8. Pediatr Rheumatol Online J. 2022. PMID: 35197077 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous